Show simple item record

dc.contributor.authorDodson, Aen_US
dc.contributor.authorParry, Sen_US
dc.contributor.authorIbrahim, Men_US
dc.contributor.authorBartlett, JMen_US
dc.contributor.authorPinder, Sen_US
dc.contributor.authorDowsett, Men_US
dc.contributor.authorMiller, Ken_US
dc.date.accessioned2018-08-08T15:05:10Z
dc.date.issued2018-10en_US
dc.identifier.citationThe journal of pathology. Clinical research, 2018, 4 (4), pp. 262 - 273en_US
dc.identifier.issn2056-4538en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2309
dc.identifier.eissn2056-4538en_US
dc.identifier.doi10.1002/cjp2.112en_US
dc.description.abstractWe describe a collated data set of results from clinical testing of breast cancers carried out between 2009 and 2016 in the United Kingdom and Republic of Ireland. More than 199 000 patient biomarker data sets, together with clinicopathological parameters were collected. Our analyses focused on human epidermal growth factor receptor-2 (HER2), oestrogen receptor (ER) and progesterone receptor (PR), with the aim of the study being to provide robust confirmatory evidence on known associations in these biomarkers and to uncover new data on previously undescribed or unconfirmed associations, thus strengthening the evidence-base in clinical breast cancer testing. Overall, 13.1% of tumours were HER2-positive; 10.6% in ER-positive tumours, and 25.5% in ER-negative tumours. Higher rates of HER2 positivity were significantly associated with patient age <56 years versus age ≥56 years, symptomatic versus screen-detected tumours, testing of involved axillary node versus primary breast cancer, invasive ductal carcinoma (not otherwise specified) versus other histological types, higher histological grade, increasing tumour size, increasing nodal involvement, ER-negative versus ER-positive tumour status, PR-negative versus PR-positive tumour status. Where ER status was known, 82.7% of tumours were ER-positive; 80.9% in women age <56 years, and 83.6% in those age ≥56 years (ER-positive cut-off ≥1.0% positive tumour cells or equivalent). Where PR status was known, 64.9% of tumours were PR-positive; 65.8% in women age <56 years, and 64.4% in women age ≥56 years (PR-positive cut off ≥10.0% or equivalent). These analyses of clinical test results provide contemporary benchmarking data for HER2, ER and PR positive rates.en_US
dc.formatPrint-Electronicen_US
dc.format.extent262 - 273en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumansen_US
dc.subjectBreast Neoplasmsen_US
dc.subjectReceptor, erbB-2en_US
dc.subjectEstrogen Receptor alphaen_US
dc.subjectReceptors, Progesteroneen_US
dc.subjectImmunohistochemistryen_US
dc.subjectIn Situ Hybridizationen_US
dc.subjectDatabases, Factualen_US
dc.subjectIrelanden_US
dc.subjectFemaleen_US
dc.subjectBiomarkers, Tumoren_US
dc.subjectUnited Kingdomen_US
dc.titleBreast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-07-27en_US
rioxxterms.versionofrecord10.1002/cjp2.112en_US
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc/4.0en_US
rioxxterms.licenseref.startdate2018-10en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfThe journal of pathology. Clinical researchen_US
pubs.issue4en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Endocrinology/Endocrinology (hon.)
pubs.publication-statusPublisheden_US
pubs.volume4en_US
pubs.embargo.termsNot knownen_US
icr.researchteamEndocrinologyen_US
dc.contributor.icrauthorDowsett, Mitchen_US


Files in this item

Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/